Immunic

$15.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.25%) As of 4:12 PM UTC today

Why Robinhood?

You can buy or sell Immunic and other stocks, options, and ETFs commission-free!

About IMUX

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA. The listed name for IMUX is Immunic, Inc. Common Stock.

CEO

Daniel Vitt

Employees

Headquarters

New York, New York

Founded

—

Market Cap

347.56M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

545.60K

High Today

$16.51

Low Today

$15.78

Open Price

$16.19

Volume

114.65K

52 Week High

$28.21

52 Week Low

$4.19

IMUX Earnings

-$1.52

-$1.01

-$0.51

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

-$0.42 per share